Parabilis Medicines, Inc.
PBLSHeld by 7 specialist biotech funds
High Convergence7 funds opened new positions. Next phase2 readout (FOG-001): Apr 2027. Short interest: 6.8% of float.
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.